A meta-analysis of 9 trials found that GLP-1 receptor agonists significantly reduced body fat in type 2 diabetes patients with sarcopenia while preserving lean muscle mass.
Muscle mass preserved (p=0.31)Lean body mass did not significantly decrease with GLP-1 receptor agonist treatment in sarcopenic diabetic patients, while fat mass dropped significantly by 8 kg.
What the researchers found
Across 9 randomized controlled trials with 1,089 participants, GLP-1 receptor agonists produced significant reductions in fat-related measures: body fat ratio decreased (MD = -2.76, p < 0.01), fat mass decreased (MD = -8.00, p < 0.01), and BMI decreased (MD = -1.83, p < 0.01).
Critically, muscle-related measures were not significantly affected: lean body mass showed a non-significant increase (MD = +4.61, p = 0.31) and skeletal muscle index was also unchanged (MD = +0.59, p = 0.19). Body weight change overall was not statistically significant (MD = -2.25, p = 0.20), suggesting the weight composition shifted favorably from fat to a relatively preserved lean mass.
Why it matters
The fear of losing muscle mass on GLP-1 drugs has been a major concern for both clinicians and patients, particularly in populations already vulnerable to sarcopenia. This meta-analysis directly addresses that concern in the highest-risk group — older adults with type 2 diabetes who already have muscle wasting. The finding that fat is preferentially lost while muscle is preserved is clinically reassuring and could influence prescribing decisions for this population.
How the study worked
Systematic review and meta-analysis of randomized controlled trials, registered on PROSPERO (CRD42023473528). Nine databases including PubMed, Embase, Cochrane Library, Web of Science, and four Chinese databases were searched through July 2025. Grey literature sources were also included. Random effects models were used regardless of heterogeneity. Publication bias was assessed with funnel plots.
What this study cannot tell us
Only 9 trials with 1,089 total participants were included, which is relatively small for a meta-analysis. The body weight reduction was not statistically significant (p = 0.20), which may indicate underpowering or heterogeneity across trials. Different GLP-1 receptor agonists were pooled regardless of structure, though subtype differences may exist. Methods of measuring body composition varied across studies. Trial durations were not specified in the abstract, making it unclear whether longer-term muscle effects might differ.
How to read the evidence
This is a registered systematic review and meta-analysis of 9 randomized controlled trials — strong evidence synthesis methodology. However, the relatively small number of included trials and participants, along with some non-significant primary outcomes, tempers the certainty of conclusions.
When this study was published
Published in 2025 with database searches through July 2025, this is very current and addresses one of the most pressing questions in GLP-1 therapy — whether these drugs cause harmful muscle loss during weight reduction.
The bigger picture
As GLP-1 receptor agonists become first-line weight loss treatments, understanding their effects on body composition — not just total weight — is crucial. Previous concerns were fueled by the STEP trials showing semaglutide users lost some lean mass alongside fat. This meta-analysis, focusing specifically on sarcopenic diabetic patients, provides evidence that muscle wasting is not a significant consequence of GLP-1 therapy, at least in this population. This complements the growing narrative that these peptide drugs may have a more favorable body composition profile than previously feared.
Questions still open
- Do specific GLP-1 receptor agonists (e.g., semaglutide vs. liraglutide vs. tirzepatide) differ in their effects on muscle preservation in sarcopenic patients?
- Would combining GLP-1 drugs with resistance exercise training further protect or even increase muscle mass in this population?
- How do the muscle-preservation findings in sarcopenic diabetic patients compare to non-diabetic obese patients on the same medications?
Common questions
Will taking a GLP-1 drug like semaglutide make me lose muscle?
What is sarcopenia and why does it matter for people on weight-loss drugs?
Read the original research
Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis.
Diabetology & metabolic syndrome, 17(1), 315
Citation
Wang, Yanying; Lan, Boya; Zhang, Shuo; Mu, Yue; Mi, Jia; Yu, Jing; Zhan, Qun; Luo, Baoling; Lin, Fuyang; Teng, Jia; Wang, Xiuge; Yan, Guanchi. (2025). Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis.. Diabetology & metabolic syndrome, 17(1), 315. https://doi.org/10.1186/s13098-025-01877-4